The small drug firms set to benefit from RSV vaccines

Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK.

Chances are RSV, or respiratory syncytial virus, which has symptoms similar to the common cold.

It is a highly contagious disease that affects people of all ages, but can be especially dangerous for the elderly.

AIM-listed Synairgen is developing a broad treatment that could potentially fight both flu and RSV Poolbeg Pharma has identified and developed a preclinical agent using artificial intelligence – a world first.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma

Poolbeg Pharma could reach €1bn valuation

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici for $1.48

Poolbeg Pharma

The role of AI in Drug Discovery and Healthcare

Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in 2022, is projected to grow at a CAGR

hVIVO plc

Should we be worried about the new swine flu strain?

‘Don’t panic but stay alert’. That is the advice from a top London scientist after the first confirmed human case of a new strain of swine flu in the UK. The virus was only spotted when a patient in North

Poolbeg Pharma

The impact of Artificial Intelligence in the pharmaceutical industry

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new

Poolbeg Pharma

Amryt trio join Poolbeg leadership team

Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. These experienced professionals will assume pivotal roles within

hVIVO plc

Challenge Trials: A long term growth trend

hVIVO is the only global CRO focused on the delivery of human challenge trials, with its heritage dating back to the 1940s Common Cold Unit, and is spearheading a long term growth trend in the HCT market. HCTs,

Poolbeg Pharma

Poolbeg Pharma Immunomodulator II patent granted in Japan

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Japanese Patent Office has notified the Company of its official decision

Poolbeg Pharma

AI is taking drug discovery by storm

Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered into partnerships or licensing agreements with AI companies

Poolbeg Pharma

Poolbeg Pharma POLB 001 LPS Challenge Trial data to be presented at IUIS

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted

hVIVO plc

Fueling Scientific Research

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

Poolbeg Pharma

Key senior members of former Amryt Pharma leadership join Poolbeg Pharma

Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both

Poolbeg Pharma

Former Amryt Pharma leadership team to join Poolbeg

Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma. David Allmond, John McEvoy and Laura Maher will join the company in the coming months. Allmond will become chief business officer

hVIVO plc

hVIVO at Jefferies Healthcare Conference

hVIVO will be attending the Jefferies Healthcare Conference: Start Date: 14 Nov 2023 End date: 16 Nov 2023 Location: London, UK hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world

Poolbeg Pharma

The potential of AI in Drug Discovery and its impact on Healthcare

The discove­ry of new drugs has always been a challe­nging and expensive proce­ss. It involves extensive­ timeframes and significant costs, which have long highlighte­d the need for re­form in this critical field. Despite pre­vious efforts to accelerate drug

No more posts to show